Investors focused on the Medical space have likely heard of Lannett Co (LCI), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Lannett Co is a member of our Medical group, which includes 844 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LCI is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for LCI's full-year earnings has moved 2.90% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, LCI has returned 20.97% so far this year. Meanwhile, stocks in the Medical group have gained about 2.82% on average. As we can see, Lannett Co is performing better than its sector in the calendar year.
Breaking things down more, LCI is a member of the Medical - Drugs industry, which includes 174 individual companies and currently sits at #69 in the Zacks Industry Rank. On average, this group has gained an average of 5.31% so far this year, meaning that LCI is performing better in terms of year-to-date returns.
LCI will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Lannett Co Inc (LCI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research